$VRDN
Viridian Therapeutics, Inc.\DE Stock $vrdn

$vrdn Overview Financials Valuation SEC Filings Company Website

2024 Q3 Form 10-Q Financial Statement

#000159075024000019 Filed on August 08, 2024

Income Statement

Concept	2024 Q3	2024 Q2	2023 Q4
Revenue	$86.00K	$72.00K	$72.00K
YoY Change	19.44%	0.0%	-31.43%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$14.41M	$16.07M	$32.99M
YoY Change	-31.1%	-16.6%	234.82%
% of Gross Profit
Research & Development	$69.16M	$56.19M	$38.56M
YoY Change	127.61%	40.19%	-1.93%
% of Gross Profit
Depreciation & Amortization	$130.0K	$142.0K	$150.0K
YoY Change	0.0%	7.58%	56.25%
% of Gross Profit
Operating Expenses	$83.57M	$72.26M	$71.55M
YoY Change	62.91%	21.76%	45.51%
Operating Profit	-$83.48M	-$72.19M
YoY Change	62.97%	21.78%
Interest Expense	$6.791M	$7.194M	$4.618M
YoY Change	90.76%	3497.0%	40.75%
% of Operating Profit
Other Income/Expense, Net	$6.791M	$7.194M
YoY Change	90.54%	70.8%
Pretax Income	-$76.69M	-$64.99M	-$66.86M
YoY Change	60.91%	18.03%	46.03%
Income Tax
% Of Pretax Income
Net Earnings	-$76.69M	-$64.99M	-$66.86M
YoY Change	60.91%	18.03%	46.03%
Net Earnings / Revenue	-89173.26%	-90268.06%	-92861.11%
Basic Earnings Per Share	-$1.15	-$1.02
Diluted Earnings Per Share	-$1.15	-$1.02	-$1.34
COMMON SHARES
Basic Shares Outstanding	63.89M shares	63.82M shares	52.59M shares
Diluted Shares Outstanding	66.42M shares	63.85M shares

Balance Sheet

Concept	2024 Q3	2024 Q2	2023 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments	$753.2M	$571.4M	$477.4M
YoY Change	140.65%	70.92%	12.44%
Cash & Equivalents	$200.3M	$107.7M	$102.8M
Short-Term Investments	$552.9M	$463.7M	$374.5M
Other Short-Term Assets	$14.10M	$10.30M	$9.006M
YoY Change	31.8%	-13.74%	38.11%
Inventory
Prepaid Expenses
Receivables	$14.00K	$0.00	$102.0K
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$767.4M	$581.7M	$486.5M
YoY Change	136.96%	67.95%	12.83%
LONG-TERM ASSETS
Property, Plant & Equipment	$1.290M	$1.514M	$1.672M
YoY Change	-28.33%	-19.55%	26.09%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$853.0K	$659.0K	$604.0K
YoY Change	-32.46%	-44.34%	-38.49%
Total Long-Term Assets	$4.543M	$3.999M	$3.946M
YoY Change	-7.63%	-22.14%	0.71%
TOTAL ASSETS
Total Short-Term Assets	$767.4M	$581.7M	$486.5M
Total Long-Term Assets	$4.543M	$3.999M	$3.946M
Total Assets	$771.9M	$585.7M	$490.4M
YoY Change	134.79%	66.63%	12.72%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$6.338M	$3.140M	$2.239M
YoY Change	69.69%	-24.03%	-84.27%
Accrued Expenses	$34.74M	$30.37M	$24.11M
YoY Change	80.7%	25.31%	28.05%
Deferred Revenue	$288.0K	$288.0K	$288.0K
YoY Change	0.0%	0.0%	0.0%
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due		$2.964M	$0.00
YoY Change
Total Short-Term Liabilities	$41.36M	$36.76M	$26.64M
YoY Change	77.93%	28.28%	-20.13%
LONG-TERM LIABILITIES
Long-Term Debt	$20.52M	$17.49M	$20.21M
YoY Change	2.62%	271.35%	334.98%
Other Long-Term Liabilities	$2.161M	$1.648M	$989.0K
YoY Change	67.65%	7.92%	-15.61%
Total Long-Term Liabilities	$22.68M	$19.14M	$989.0K
YoY Change	1659.81%	1153.11%	-15.61%
TOTAL LIABILITIES
Total Short-Term Liabilities	$41.36M	$36.76M	$26.64M
Total Long-Term Liabilities	$22.68M	$19.14M	$989.0K
Total Liabilities	$64.40M	$56.33M	$48.40M
YoY Change	42.55%	58.17%	20.92%
SHAREHOLDERS EQUITY
Retained Earnings	-$916.1M	-$839.4M	-$725.9M
YoY Change	39.01%	37.29%	48.69%
Common Stock	$792.0K	$639.0K	$540.0K
YoY Change	81.24%	46.56%	30.43%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$707.5M	$529.3M	$442.0M
YoY Change
Total Liabilities & Shareholders Equity	$771.9M	$585.7M	$490.4M
YoY Change	134.79%	66.63%	12.72%

Cashflow Statement

Concept	2024 Q3	2024 Q2	2023 Q4
OPERATING ACTIVITIES
Net Income	-$76.69M	-$64.99M	-$66.86M
YoY Change	60.91%	18.03%	46.03%
Depreciation, Depletion And Amortization	$130.0K	$142.0K	$150.0K
YoY Change	0.0%	7.58%	56.25%
Cash From Operating Activities	-$67.71M	-$46.06M	-$38.00M
YoY Change	73.69%	1.87%	11.63%
INVESTING ACTIVITIES
Capital Expenditures	$293.0K	$104.0K	$48.00K
YoY Change	-26.75%	-68.58%	-79.22%
Acquisitions
YoY Change
Other Investing Activities	-$84.37M	$62.08M	-$169.7M
YoY Change	-274.15%	51.25%	-5.94%
Cash From Investing Activities	-$84.67M	$61.98M	-$169.7M
YoY Change	-276.24%	52.23%	-6.03%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	245.0M	108.0K	198.9M
YoY Change	1484.88%	-96.48%	664.75%
NET CHANGE
Cash From Operating Activities	-67.71M	-46.06M	-38.00M
Cash From Investing Activities	-84.67M	61.98M	-169.7M
Cash From Financing Activities	245.0M	108.0K	198.9M
Net Change In Cash	92.65M	16.03M	-8.770M
YoY Change	277.85%	-1218.35%	-95.35%
FREE CASH FLOW
Cash From Operating Activities	-$67.71M	-$46.06M	-$38.00M
Capital Expenditures	$293.0K	$104.0K	$48.00K
Free Cash Flow	-$68.00M	-$46.16M	-$38.05M
YoY Change	72.67%	1.35%	11.01%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2024Q2	us-gaap	Stockholders Equity StockholdersEquity	529338000	usd
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.82
CY2024Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	63854514	shares
CY2024Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	63854514	shares
CY2023Q2	vrdn	Stock Issued During Period Value Warrants Exercised Value StockIssuedDuringPeriodValueWarrantsExercisedValue	935000	usd
CY2023Q2	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	2133000	usd
	dei	Entity Central Index Key EntityCentralIndexKey	0001590750
	dei	Amendment Flag AmendmentFlag	false
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2024
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q2
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Entity Registrant Name EntityRegistrantName	Viridian Therapeutics, Inc./DE
CY2023Q4	us-gaap	Operating Lease Liability Current Statement Of Financial Position Extensible List OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2024#AccruedLiabilitiesCurrent
CY2024Q2	us-gaap	Operating Lease Liability Current Statement Of Financial Position Extensible List OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2024#AccruedLiabilitiesCurrent
CY2024Q2	us-gaap	Operating Lease Liability Current Statement Of Financial Position Extensible List OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2024#AccruedLiabilitiesCurrent
CY2024Q2	us-gaap	Operating Lease Liability Noncurrent Statement Of Financial Position Extensible List OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2024#OtherLiabilitiesNoncurrent
	dei	Security12b Title Security12bTitle	Common Stock, $0.01 par value per share
	dei	Trading Symbol TradingSymbol	VRDN
	dei	Security Exchange Name SecurityExchangeName	NASDAQ
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
	dei	Entity Filer Category EntityFilerCategory	Large Accelerated Filer
	dei	Entity Small Business EntitySmallBusiness	false
	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
	dei	Entity Shell Company EntityShellCompany	false
CY2024Q3	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	63889920	shares
CY2024Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	107667000	usd
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	102827000	usd
CY2024Q2	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	463699000	usd
CY2023Q4	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	374543000	usd
CY2024Q2	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	10298000	usd
CY2023Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	9006000	usd
CY2024Q2	us-gaap	Contract With Customer Asset Net ContractWithCustomerAssetNet	0	usd
CY2023Q4	us-gaap	Contract With Customer Asset Net ContractWithCustomerAssetNet	102000	usd
CY2024Q2	us-gaap	Assets Current AssetsCurrent	581664000	usd
CY2023Q4	us-gaap	Assets Current AssetsCurrent	486478000	usd
CY2024Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1514000	usd
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1672000	usd
CY2024Q2	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	1826000	usd
CY2023Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	1670000	usd
CY2024Q2	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	659000	usd
CY2023Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	604000	usd
CY2024Q2	us-gaap	Assets Assets	585663000	usd
CY2023Q4	us-gaap	Assets Assets	490424000	usd
CY2024Q2	us-gaap	Accounts Payable Current AccountsPayableCurrent	3140000	usd
CY2023Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	2239000	usd
CY2024Q2	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	30370000	usd
CY2023Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	24108000	usd
CY2024Q2	us-gaap	Long Term Debt Current LongTermDebtCurrent	2964000	usd
CY2023Q4	us-gaap	Long Term Debt Current LongTermDebtCurrent	0	usd
CY2024Q2	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	288000	usd
CY2023Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	288000	usd
CY2024Q2	us-gaap	Liabilities Current LiabilitiesCurrent	36762000	usd
CY2023Q4	us-gaap	Liabilities Current LiabilitiesCurrent	26635000	usd
CY2024Q2	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	17487000	usd
CY2023Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	20205000	usd
CY2024Q2	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	428000	usd
CY2023Q4	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	573000	usd
CY2024Q2	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	1648000	usd
CY2023Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	989000	usd
CY2024Q2	us-gaap	Liabilities Liabilities	56325000	usd
CY2023Q4	us-gaap	Liabilities Liabilities	48402000	usd
CY2024Q2	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2023Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2023Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2024Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2023Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	200000000	shares
CY2024Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	200000000	shares
CY2024Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	63879675	shares
CY2024Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	63879675	shares
CY2023Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	53986112	shares
CY2023Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	53986112	shares
CY2024Q2	us-gaap	Common Stock Value CommonStockValue	639000	usd
CY2023Q4	us-gaap	Common Stock Value CommonStockValue	540000	usd
CY2024Q2	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	1168975000	usd
CY2023Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	960536000	usd
CY2024Q2	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-543000	usd
CY2023Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	338000	usd
CY2024Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-839443000	usd
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-725908000	usd
CY2024Q2	us-gaap	Stockholders Equity StockholdersEquity	529338000	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	442022000	usd
CY2024Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	585663000	usd
CY2023Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	490424000	usd
CY2024Q2	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	72000	usd
CY2023Q2	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	72000	usd
	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	144000	usd
	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	170000	usd
CY2024Q2	us-gaap	Research And Development Expense Excluding Acquired In Process Cost ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost	56193000	usd
CY2023Q2	us-gaap	Research And Development Expense Excluding Acquired In Process Cost ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost	40083000	usd
	us-gaap	Research And Development Expense Excluding Acquired In Process Cost ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost	97136000	usd
	us-gaap	Research And Development Expense Excluding Acquired In Process Cost ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost	90823000	usd
CY2024Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	16066000	usd
CY2023Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	19264000	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	31091000	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	41095000	usd
CY2024Q2	us-gaap	Operating Expenses OperatingExpenses	72259000	usd
CY2023Q2	us-gaap	Operating Expenses OperatingExpenses	59347000	usd
	us-gaap	Operating Expenses OperatingExpenses	128227000	usd
	us-gaap	Operating Expenses OperatingExpenses	131918000	usd
CY2024Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-72187000	usd
CY2023Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-59275000	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-128083000	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-131748000	usd
CY2024Q2	us-gaap	Interest And Other Income InterestAndOtherIncome	7791000	usd
CY2023Q2	us-gaap	Interest And Other Income InterestAndOtherIncome	4378000	usd
	us-gaap	Interest And Other Income InterestAndOtherIncome	15732000	usd
	us-gaap	Interest And Other Income InterestAndOtherIncome	8865000	usd
CY2024Q2	us-gaap	Interest Expense Nonoperating InterestExpenseNonoperating	597000	usd
CY2023Q2	us-gaap	Interest Expense Nonoperating InterestExpenseNonoperating	166000	usd
	us-gaap	Interest Expense Nonoperating InterestExpenseNonoperating	1184000	usd
	us-gaap	Interest Expense Nonoperating InterestExpenseNonoperating	331000	usd
CY2024Q2	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	7194000	usd
CY2023Q2	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	4212000	usd
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	14548000	usd
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	8534000	usd
CY2024Q2	us-gaap	Net Income Loss NetIncomeLoss	-64993000	usd
CY2023Q2	us-gaap	Net Income Loss NetIncomeLoss	-55063000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-113535000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-123214000	usd
CY2024Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.02
CY2024Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.02
CY2023Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.27
CY2023Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.27
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.82
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-2.88
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-2.88
CY2023Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	43253457	shares
CY2023Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	43253457	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	62476777	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	62476777	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	42753476	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	42753476	shares
CY2024Q2	us-gaap	Net Income Loss NetIncomeLoss	-64993000	usd
CY2023Q2	us-gaap	Net Income Loss NetIncomeLoss	-55063000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-113535000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-123214000	usd
CY2024Q2	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	-176000	usd
CY2023Q2	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	1000	usd
	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	-881000	usd
	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	217000	usd
CY2024Q2	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-176000	usd
CY2023Q2	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	1000	usd
	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	-881000	usd
	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	217000	usd
CY2024Q2	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-65169000	usd
CY2023Q2	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-55062000	usd
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-114416000	usd
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-122997000	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	442022000	usd
CY2024Q1	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	0	usd
CY2024Q1	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	838000	usd
CY2024Q1	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	356000	usd
CY2024Q1	us-gaap	Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures	0	usd
CY2024Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	12688000	usd
CY2024Q1	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	-705000	usd
CY2024Q1	us-gaap	Net Income Loss NetIncomeLoss	-48542000	usd
CY2024Q1	us-gaap	Stockholders Equity StockholdersEquity	582530000	usd
CY2024Q2	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	210000	usd
CY2024Q2	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	11767000	usd
CY2024Q2	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	-176000	usd
CY2024Q2	us-gaap	Net Income Loss NetIncomeLoss	-64993000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	395064000	usd
CY2023Q1	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	0	usd
CY2023Q1	vrdn	Stock Issued During Period Value Warrants Exercised Value StockIssuedDuringPeriodValueWarrantsExercisedValue	946000	usd
CY2023Q1	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	6938000	usd
CY2023Q1	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	320000	usd
CY2023Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	15216000	usd
CY2023Q1	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	216000	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-68151000	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	350549000	usd
CY2023Q2	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	5000000	usd
CY2023Q2	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	12302000	usd
CY2023Q2	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	1000	usd
CY2023Q2	us-gaap	Net Income Loss NetIncomeLoss	-55063000	usd
CY2023Q2	us-gaap	Stockholders Equity StockholdersEquity	315857000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-113535000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-123214000	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	24455000	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	27518000	usd
	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	0	usd
	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	5000000	usd
	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	246000	usd
	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	107000	usd
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	287000	usd
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	237000	usd
	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	9071000	usd
	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	5884000	usd
	vrdn	Non Cash Lease Expense NonCashLeaseExpense	167000	usd
	vrdn	Non Cash Lease Expense NonCashLeaseExpense	-24000	usd
	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	0	usd
	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	-31000	usd
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	1346000	usd
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	5617000	usd
	us-gaap	Increase Decrease In Contract With Customer Asset IncreaseDecreaseInContractWithCustomerAsset	-102000	usd
	us-gaap	Increase Decrease In Contract With Customer Asset IncreaseDecreaseInContractWithCustomerAsset	0	usd
	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	-144000	usd
	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	-144000	usd
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	920000	usd
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-10416000	usd
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	6638000	usd
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	5219000	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-91281000	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-107187000	usd
	us-gaap	Payments To Acquire Available For Sale Securities Debt PaymentsToAcquireAvailableForSaleSecuritiesDebt	284867000	usd
	us-gaap	Payments To Acquire Available For Sale Securities Debt PaymentsToAcquireAvailableForSaleSecuritiesDebt	85336000	usd
	us-gaap	Proceeds From Sale And Maturity Of Available For Sale Securities ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities	203902000	usd
	us-gaap	Proceeds From Sale And Maturity Of Available For Sale Securities ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities	113200000	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	104000	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	446000	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-81069000	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	27418000	usd
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	186265000	usd
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	0	usd
	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	10479000	usd
	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	0	usd
	us-gaap	Proceeds From Issuance Of Warrants ProceedsFromIssuanceOfWarrants	0	usd
	us-gaap	Proceeds From Issuance Of Warrants ProceedsFromIssuanceOfWarrants	1881000	usd
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	1048000	usd
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	9071000	usd
	us-gaap	Proceeds From Stock Plans ProceedsFromStockPlans	356000	usd
	us-gaap	Proceeds From Stock Plans ProceedsFromStockPlans	320000	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	177190000	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	11272000	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	4840000	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-68497000	usd
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	102827000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	155579000	usd
CY2024Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	107667000	usd
CY2023Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	87082000	usd
	us-gaap	Interest Paid Net InterestPaidNet	910000	usd
	us-gaap	Interest Paid Net InterestPaidNet	226000	usd
	us-gaap	Conversion Of Stock Amount Issued1 ConversionOfStockAmountIssued1	6806000	usd
	us-gaap	Conversion Of Stock Amount Issued1 ConversionOfStockAmountIssued1	7235000	usd
	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	26000	usd
	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	314000	usd
CY2024Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-839400000	usd
CY2024Q2	us-gaap	Cash Cash Equivalents And Short Term Investments CashCashEquivalentsAndShortTermInvestments	571400000	usd
	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1	segment
	us-gaap	Use Of Estimates UseOfEstimates	<div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company’s condensed consolidated financial statements are prepared in accordance with U.S. GAAP, which requires it to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and contingent liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Significant estimates and assumptions reflected in these condensed consolidated financial statements include, but are not limited to, the accrual for clinical trial costs, including manufacturing activities, and other outsourced research and development expenses, and the valuation of share-based awards. Although these estimates are based on the Company’s knowledge of current events and actions it may take in the future, actual results may ultimately differ from these estimates and assumptions.</span></div>
	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<div style="margin-bottom:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Concentrations of Credit Risk</span></div>Financial instruments that potentially subject the Company to concentrations of credit risk consist primarily of cash equivalents, which include short-term investments that have maturities of less than three months. The Company maintains deposits in federally insured financial institutions in excess of federally insured limits. The Company has not experienced any losses in such accounts. The Company invests its excess cash primarily in deposits and money market funds held with one financial institution. The Company does not believe that it is subject to unusual credit risk beyond the normal credit risk associated with commercial banking relationships.
	us-gaap	Impairment Of Long Lived Assets Held For Use ImpairmentOfLongLivedAssetsHeldForUse	0	usd
	us-gaap	Impairment Of Long Lived Assets Held For Use ImpairmentOfLongLivedAssetsHeldForUse	0	usd
CY2024Q2	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	0	usd
	us-gaap	Income Tax Examination Penalties And Interest Expense IncomeTaxExaminationPenaltiesAndInterestExpense	0	usd
	us-gaap	Income Tax Examination Penalties And Interest Expense IncomeTaxExaminationPenaltiesAndInterestExpense	0	usd
	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1	segment
CY2024Q2	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	564994000	usd
CY2024Q2	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	30000	usd
CY2024Q2	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	573000	usd
CY2024Q2	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	564451000	usd
CY2023Q4	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	462914000	usd
CY2023Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	428000	usd
CY2023Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	90000	usd
CY2023Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	463252000	usd
CY2023Q2	us-gaap	Debt Securities Available For Sale Realized Gain Loss DebtSecuritiesAvailableForSaleRealizedGainLoss	0	usd
CY2024Q2	us-gaap	Debt Securities Available For Sale Realized Gain Loss DebtSecuritiesAvailableForSaleRealizedGainLoss	0	usd
	us-gaap	Debt Securities Available For Sale Realized Gain Loss DebtSecuritiesAvailableForSaleRealizedGainLoss	0	usd
	us-gaap	Debt Securities Available For Sale Realized Gain Loss DebtSecuritiesAvailableForSaleRealizedGainLoss	0	usd
CY2024Q2	us-gaap	Proceeds From Sale Of Available For Sale Securities Debt ProceedsFromSaleOfAvailableForSaleSecuritiesDebt	0	usd
CY2023Q2	us-gaap	Proceeds From Sale Of Available For Sale Securities Debt ProceedsFromSaleOfAvailableForSaleSecuritiesDebt	0	usd
	us-gaap	Proceeds From Sale Of Available For Sale Securities Debt ProceedsFromSaleOfAvailableForSaleSecuritiesDebt	0	usd
	us-gaap	Proceeds From Sale Of Available For Sale Securities Debt ProceedsFromSaleOfAvailableForSaleSecuritiesDebt	0	usd
CY2024Q2	us-gaap	Debt Securities Available For Sale Term DebtSecuritiesAvailableForSaleTerm	P24M
CY2024Q2	vrdn	Accrued Outsourcing Clinicaland Preclinical Studies AccruedOutsourcingClinicalandPreclinicalStudies	18397000	usd
CY2023Q4	vrdn	Accrued Outsourcing Clinicaland Preclinical Studies AccruedOutsourcingClinicalandPreclinicalStudies	10724000	usd
CY2024Q2	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	9037000	usd
CY2023Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	10513000	usd
CY2024Q2	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	507000	usd
CY2023Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	843000	usd
CY2024Q2	vrdn	Accrued Legal Fees Current AccruedLegalFeesCurrent	591000	usd
CY2023Q4	vrdn	Accrued Legal Fees Current AccruedLegalFeesCurrent	399000	usd
CY2024Q2	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	999000	usd
CY2023Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	473000	usd
CY2024Q2	vrdn	Accrued Liabilityof Warrantson Temporary Equity AccruedLiabilityofWarrantsonTemporaryEquity	100000	usd
CY2023Q4	vrdn	Accrued Liabilityof Warrantson Temporary Equity AccruedLiabilityofWarrantsonTemporaryEquity	100000	usd
CY2024Q2	us-gaap	Interest Payable Current InterestPayableCurrent	149000	usd
CY2023Q4	us-gaap	Interest Payable Current InterestPayableCurrent	154000	usd
CY2024Q2	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	590000	usd
CY2023Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	902000	usd
CY2024Q2	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	30370000	usd
CY2023Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	24108000	usd
	vrdn	Lessee Operating Lease Number Of Renewal Terms LesseeOperatingLeaseNumberOfRenewalTerms	3	renewal_term
CY2024Q2	us-gaap	Lessee Operating Lease Renewal Term LesseeOperatingLeaseRenewalTerm	P3Y
CY2021Q1	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	1600000	usd
CY2021Q1	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	1600000	usd
CY2021Q1	us-gaap	Lessee Operating Lease Discount Rate LesseeOperatingLeaseDiscountRate	0.06
CY2021Q1	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P12M
CY2020Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	100000	usd
CY2020Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	100000	usd
CY2020Q4	us-gaap	Lessee Operating Lease Discount Rate LesseeOperatingLeaseDiscountRate	0.06
CY2024Q2	us-gaap	Area Of Real Estate Property AreaOfRealEstateProperty	10427	sqft
CY2024Q1	us-gaap	Area Of Real Estate Property AreaOfRealEstateProperty	10956	sqft
CY2024Q2	us-gaap	Lessee Operating Lease Term Of Contract LesseeOperatingLeaseTermOfContract	P5Y
CY2024Q2	vrdn	Operating Lease Annual Base Rent OperatingLeaseAnnualBaseRent	500000	usd
CY2024Q2	us-gaap	Lessee Operating Lease Renewal Term LesseeOperatingLeaseRenewalTerm	P3Y
CY2024Q2	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	1600000	usd
CY2024Q2	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	1900000	usd
CY2024Q2	vrdn	Operating Lease Right Of Use Asset Derecognized OperatingLeaseRightOfUseAssetDerecognized	1100000	usd
CY2024Q2	vrdn	Operating Lease Liability Current Derecognized OperatingLeaseLiabilityCurrentDerecognized	1200000	usd
CY2024Q2	us-gaap	Lessee Operating Lease Liability Payments Remainder Of Fiscal Year LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear	445000	usd
CY2024Q2	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	463000	usd
CY2024Q2	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	474000	usd
CY2024Q2	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	484000	usd
CY2024Q2	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	494000	usd
CY2024Q2	us-gaap	Lessee Operating Lease Liability Payments Due Year Five LesseeOperatingLeaseLiabilityPaymentsDueYearFive	292000	usd
CY2024Q2	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	2652000	usd
CY2024Q2	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	498000	usd
CY2024Q2	us-gaap	Operating Lease Liability OperatingLeaseLiability	2154000	usd
CY2024Q2	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	500000	usd
CY2024Q2	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	1600000	usd
CY2024Q2	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	300000	usd
	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	600000	usd
CY2023Q2	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	300000	usd
	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	400000	usd
CY2024Q2	vrdn	Operating Leases Operating Expense OperatingLeasesOperatingExpense	100000	usd
	vrdn	Operating Leases Operating Expense OperatingLeasesOperatingExpense	200000	usd
CY2023Q2	vrdn	Operating Leases Operating Expense OperatingLeasesOperatingExpense	100000	usd
	vrdn	Operating Leases Operating Expense OperatingLeasesOperatingExpense	200000	usd
CY2024Q2	vrdn	Capital Stock Shares Authorized CapitalStockSharesAuthorized	205000000	shares
CY2024Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	200000000	shares
CY2024Q2	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2024Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2024Q2	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.01
CY2024Q2	vrdn	Common Stock Vote Per Share CommonStockVotePerShare	1	vote
CY2024Q2	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2024Q2	vrdn	Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights Net ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRightsNet	249883	shares
CY2023Q4	vrdn	Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights Net ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRightsNet	249883	shares
CY2024Q2	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	15.51
CY2023Q4	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	249883	shares
CY2023Q4	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	15.51
	vrdn	Class Of Warrant Or Right Exercised In Period ClassOfWarrantOrRightExercisedInPeriod	0	shares
	vrdn	Class Of Warrant Or Right Exercised In Period Weighted Average Grant Date Fair Value ClassOfWarrantOrRightExercisedInPeriodWeightedAverageGrantDateFairValue	0
CY2024Q2	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	249883	shares
CY2024Q2	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	15.51
CY2024Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	10986228	shares
CY2024Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant	4297865	shares
CY2024Q2	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	11767000	usd
CY2023Q2	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	12302000	usd
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	24455000	usd
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	27518000	usd
CY2024Q2	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions	92700000	usd
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	31890610	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	23910283	shares
CY2024Q2	ecd	Non Rule10b51 Arr Adopted Flag NonRule10b51ArrAdoptedFlag	false
CY2024Q2	ecd	Rule10b51 Arr Adopted Flag Rule10b51ArrAdoptedFlag	false
CY2024Q2	ecd	Rule10b51 Arr Trmntd Flag Rule10b51ArrTrmntdFlag	false
CY2024Q2	ecd	Non Rule10b51 Arr Trmntd Flag NonRule10b51ArrTrmntdFlag	false

Files In Submission

Name	View Source	Status
0001590750-24-000019-index-headers.html	Edgar Link	pending
0001590750-24-000019-index.html	Edgar Link	pending
0001590750-24-000019.txt	Edgar Link	pending
0001590750-24-000019-xbrl.zip	Edgar Link	pending
ex311_2024-06.htm	Edgar Link	pending
ex312_2024-06.htm	Edgar Link	pending
ex321_2024-06.htm	Edgar Link	pending
exhibit101_watchfactoryvir.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
image2a.jpg	Edgar Link	pending
image3a.jpg	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
vrdn-20240630.htm	Edgar Link	pending
vrdn-20240630.xsd	Edgar Link	pending
vrdn-20240630_cal.xml	Edgar Link	unprocessable
vrdn-20240630_def.xml	Edgar Link	unprocessable
vrdn-20240630_lab.xml	Edgar Link	unprocessable
vrdn-20240630_pre.xml	Edgar Link	unprocessable
vrdn-20240630_htm.xml	Edgar Link	completed

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$VRDN
Viridian Therapeutics, Inc.\DE Stock $vrdn

2024 Q3 Form 10-Q Financial Statement

#000159075024000019 Filed on August 08, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$VRDN Viridian Therapeutics, Inc.\DE Stock $vrdn

2024 Q3 Form 10-Q Financial Statement

#000159075024000019 Filed on August 08, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$VRDN
Viridian Therapeutics, Inc.\DE Stock $vrdn